Effectiveness of Aspiration in Treating Cardiac Implantable Electronic Device-Induced Pocket Hematoma and Characteristics of Patients with Pocket Hematoma

Hye Mi Lee¹, Jin Woo Park², Young Cheon Na², Chi Sun Yoon², Jong Hwan Kim², Nam Ho Kim³

¹Leehyemi Plastic Surgery Clinic, Gwangju; Departments of ²Plastic and Reconstructive Surgery and ³Cardiology, Wonkwang University Hospital, Iksan, Korea

Abstract

Background: Pocket hematoma is the most common complication after procedures involving cardiac implantable electronic devices (CIEDs). Furthermore, pocket hematomas increase the risk of device infection. Unless severe, a pocket hematoma is usually managed conservatively because specific treatment is unavailable. Aspiration is not recommended as it can cause infection. This study explored whether lowering the risk of infection by aseptically removing the hematoma at an early stage would be possible through aspiration, investigated the effectiveness of treatment with aspiration for pocket hematoma, and analyzed the characteristics of patients with pocket hematoma.

Methods: Via chart review, we retrospectively analyzed 570 patients who underwent CIED implantation or replacement between January 2011 and January 2021. Aspiration was performed only on grade 2 and 3 hematomas.

Results: Pocket hematomas were identified in 80 patients (14%). Of these 80 patients, 52 (65%) were treated with aspiration only; six (7.5%), with aspiration plus surgical procedure; five (6.25%), with the surgical procedure only; and 17 (21.25%), with conservative treatment. Out of 58 patients treated with aspiration only and aspiration plus surgical procedure, 52 (89.65%) were treated with aspiration only, while six (10.34%) required more procedures (e.g., hematoma evacuation, Barovac insertion, or device reposition with flap surgery). However, none of these six patients exhibited an infection symptom possibly caused by aspiration.

Conclusion: Out of 80 patients with hematoma, 58 were treated with aspiration, and none showed infection symptoms that could be caused by aspiration. This suggests that aspiration can be an effective treatment if performed aseptically.

Keywords: Hematoma; Cardiac implantable electronic devices; Treatment; Aspiration; Treatment outcome

Introduction

The number of patients receiving cardiac implantable electronic devices (CIEDs) is steadily increasing worldwide [1]. Patients who receive implantation or replacement of CIEDs such as pacemakers, implantable cardioverter-defibrillators (ICD), cardiac resynchronization therapy pacemakers (CRT-P), and CRT defibrillators (CRT-D) are often on anticoagulation and antiplatelet therapy, as they carry a high risk for severe comorbidities [2]. Pocket hematoma is the most common complication after CIED procedures, with an overall incidence of up to 15% in some patient subgroups [3-5]. Pocket hematoma is associated with factors such as patient age, comorbidities, use of anticoagulant and antiplatelet drugs, device type, implantation procedure type, and the surgeon's experience. There is a 9-fold increase in the risk of infection in patients with pocket hematoma compared to those without pocket hematoma [6]. Moreover, CIED-related infection is among the most severe complications of CIED therapy,
leading to substantially increased morbidity, prolonged hospitalization, elevated mortality risk, and additional healthcare costs [7,8]. There is no specific treatment for pocket hematoma once it occurs. Pocket hematoma is generally managed conservatively as long as it is not severe, requiring evacuation or CIED removal surgery.

Aspiration of hematoma is not a recommended treatment because it can lead to infection [6,9]. According to device registry data, early reoperation for hematoma or lead dislodgement is reportedly the strongest risk factor for CIED infection [10,11].

The present study aimed to explore whether lowering the infection risk by aseptically removing the hematoma at an early stage would be possible through aspiration. We also aimed to investigate the effectiveness of treatment with aspiration for pocket hematoma.

Methods

The charts of a total of 570 patients who had CIED implantations or replacements including pacemakers, ICD, CRT-P, and CRT-D implantation or replacement at our hospital between January 2011 and January 2021 were retrospectively analyzed. After the CIED procedure, a plastic surgeon performed wound closure in layers. When the patients were hospitalized right after undergoing the CIED procedure, a plastic surgeon and a cardiologist followed up on the patient together for pocket hematoma formation until they were discharged without any complications.

Following patient discharge, a cardiologist followed up on the patients at the outpatient clinic. If the outpatients developed a pocket hematoma, the cardiologist consulted with and referred the patients to the plastic surgeon. Thereafter, the plastic surgeon followed up with the patients until the hematoma resolved.

We referred to a recent opinion article that reported a 3-level grading system for pocket hematomas and performed aseptic aspiration after alcohol and povidone preparation on grade 2 and 3 hematomas (Fig. 1) that were highly likely to become in-

Table 1. Pocket hematoma classification system developed

| Hematoma grade | Definition                                                                                                                                 |
|---------------|------------------------------------------------------------------------------------------------------------------------------------------|
| Grade 1       | Ecchymosis or mild effusion in the pocket, no swelling or pain in the device pocket (watchful waiting)                                 |
| Grade 2       | Large effusion in the pocket, leading to swelling and resulting in functional impairment or pain in the device pocket                      |
| Grade 3       | Any pocket hematoma requiring reoperation and/or resulting in the prolongation of hospitalization (defined as extended hospitalization or rehospitalization for >24 hours, post-index surgery, primarily due to hematoma) and/or requiring interruption of OAC (defined as reversal or intentional withholding, in response to a pocket hematoma, resulting in subtherapeutic anticoagulation for >24 hours) |

OAC, oral anticoagulant.
Adapted from DE Sensi et al. Pacing Clin Electrophysiol 2015;38:909-13, with permission of John Wiley and Sons [12].
affected (Table 1) [12]. In some cases, we used an ultrasound device to detect hematoma (Fig. 2) before performing aspiration, especially when the case was severe or when we were unsure why the wound was swelling. Such cases required more careful investigation and follow-up for hematoma.

We analyzed the number of patients with hematoma, treatment methods for hematoma (conservative, aspiration, or other surgical treatment), number of aspirations, total aspiration volume when performed, and the results of aspiration. For these patients, we also conducted a chart review of underlying diseases (congestive heart failure, renal failure, thrombocytopenia) that are known to increase the risk of pocket hematoma development [13,14]. We evaluated anticoagulant and antiplatelet therapy history before undergoing the CIED procedure to investigate their relationship. Furthermore, we also analyzed the frequency of pocket hematoma, according to age and CIED type, to investigate their relationship with pocket hematoma formation.

The study was approved by the Institutional Review Board of Wonkwang University Hospital (IRB No. 2021-07-013), and the patients provided written informed consent for the publication of this study and the use of their images.

**Results**

Among those included in the study, 80 patients (14%) presented with a pocket hematoma (Table 2). In our study, hematoma occurred more frequently in men than in women. Hematoma was more frequent in older adults, especially those in their 70s (Table 3). Furthermore, in descending order of frequency, the frequency of pocket hematoma by CIED type was ICD > PPM > CRT (Table 4). The incidence of pocket hematoma was 14.4% in the “De novo” group, and 11.4% in the “Replacement” group. In the “Replacement” group, those who underwent ICD replacement showed the highest frequency (25%) (Table 5). In descending order of frequency, the most common underlining diseases were hypertension (53 patients, 66.25%), diabetes mellitus (20 patients, 25.00%), arrhythmia (45 patients, 56.25%), ischemic cardiomyopathy (22 patients, 27.50%), congestive heart failure (28 patients, 35.00%), CKD (GFR < 60 mL/min/1.73 m²) (35 patients, 43.75%), thrombocytopenia (4 patients, 5.00%), stroke (9 patients, 11.25%), and none (3 patients, 3.75%).

### Table 2. Number of hematoma cases in the study

| Hematoma | No. of patients (%) |
|----------|---------------------|
| Present  | 80 (14)             |
| Absent   | 490 (86)            |
| Total    | 570 (100)           |

### Table 3. Distribution of patients with hematoma by sex and age

| Age      | Male | Female | Total |
|----------|------|--------|-------|
| ≤60 yr   | 11   | 3      | 14 (17.5) |
| >60 yr   | 31   | 35     | 66 (82.5) |
| Total    | 42 (52.5) | 38 (47.5) | 80 (100)   |

Values are presented as number or number (%).

### Table 4. Frequency of pocket hematoma according to CIED type in patients with hematoma

| CIED type | No. of patients (n=80) | Total no. of device procedures (n=570) | Frequency (%) |
|-----------|------------------------|---------------------------------------|---------------|
| PPM       | 54                     | 425                                   | 12.70         |
| ICD       | 23                     | 118                                   | 19.49         |
| CRT-D, CRT-P | 3               | 27                                     | 11.11         |

CIED, cardiac implantable electronic device; PPM, permanent pacemaker; ICD, implantable cardioverter-defibrillator; CRT, cardiac resynchronization therapy; CRT-P, CRT pacemaker; CRT-D, CRT defibrillator.

### Table 5. Distribution by de novo and replacement of CIED in patients with hematoma

| CIED procedure | No. of patients (n=80) | Total no. of device procedures (n=570) | Frequency (%) |
|----------------|------------------------|---------------------------------------|---------------|
| De novo       | 72                     | 500                                   | 14.40         |
| Replacement    |                         |                                       |               |
| PPM            | 4                      | 49                                    | 8.16          |
| ICD            | 4                      | 16                                    | 25.00         |
| CRT            | 0                      | 5                                     | 0             |
| Total          | 8                      | 70                                    | 11.43         |

CIED, cardiac implantable electronic device; PPM, permanent pacemaker; ICD, implantable cardioverter-defibrillator; CRT, cardiac resynchronization therapy.

### Table 6. Distribution of patients with hematoma according to underlining diseases

| Underlying diseases | No. of patients with hematoma (%) (n=80) |
|---------------------|------------------------------------------|
| Present             |                                          |
| Hypertension        | 53 (66.25)                               |
| Diabetes mellitus   | 20 (25.00)                               |
| Arrhythmia          | 45 (56.25)                               |
| Ischemic cardiomyopathy | 22 (27.50)                  |
| Congestive heart failure | 28 (35.00)             |
| CKD (GFR <60 mL/min/1.73 m²) | 35 (43.75)                      |
| Thrombocytopenia    | 4 (5.00)                                 |
| Stroke              | 9 (11.25)                                 |
| None                | 3 (3.75)                                 |

CKD, chronic kidney disease; GFR, glomerular filtration rate.

---

Lee HM et al.
CIED-induced pocket hematoma treatment

https://doi.org/10.22467/jwmr.2021.01865
underlying diseases were hypertension, arrhythmia, chronic kidney disease, and congestive heart failure in patients with hematoma (Table 6). In this study, 5% of patients had underlying thrombocytopenia, which was defined as a platelet count of less than 100,000/µL. Patients with hematoma commonly presented with comorbidities. Among the 80 patients with pocket hematoma, only three patients did not have a significant medical history.

In our study, anticoagulant and antiplatelet therapies performed before admission were, in descending order of frequency, aspirin, clopidogrel, and vitamin K antagonists (Table 7). Among the 80 patients with hematoma, 52 received at least one perioperative anticoagulant and antiplatelet therapy, as against 35% of patients who did not receive any therapy (Table 8).

A total of 58 patients were treated with aspiration (Table 9), of which 52 cases were treated using aspiration only (no additional surgical procedure). The six remaining patients underwent aspiration with some type of surgical procedure. Of these patients, two underwent hematoma evacuation, Barovac insertion, and device repositioning with flap (rotation flap or latissimus dorsi flap) surgery to cover the defect of the wound after performing aspiration treatment. Three patients underwent only hematoma evacuation surgery after aspiration treatment, and one patient required only incision, hematoma rolling, and primary closure. Five patients in the surgical treatment group, whose wounds had been in poor condition since immediately after the CIED procedure, underwent hematoma evacuation, Barovac insertion, and abscess incision and drainage. There were 17 patients in the conservative treatment group. Patients treated with aspiration were divided into one to five aspiration attempts. Most commonly, the patients underwent one or two aspiration procedures (87.93%). Patients were grouped in terms of aspiration volume (volume ≤10 mL, >10 and ≤20 mL, >20 and ≤30 mL, >30 and ≤40 mL, 40 mL or higher). Most patients had an aspiration volume of ≤20 mL (74.13%). Of all the hematoma cases treated only with aspiration, 89.65% were treated without any complications (Table 10).

**Table 7.** Distribution of patients with hematoma according to anticoagulant and antiplatelet therapy (before admission)

| Anticoagulant and antiplatelet therapy agents | No. of patients with hematoma (%) (n=80) |
|---------------------------------------------|----------------------------------------|
| Aspirin                                     | 31 (38.75)                             |
| Clopidogrel                                  | 23 (28.75)                             |
| Cilostazol                                   | 5 (6.25)                               |
| Vitamin K antagonist                         | 8 (10.00)                              |
| Heparin                                      | 2 (2.50)                               |
| Novel oral anticoagulant                     | 6 (7.50)                               |
| None                                         | 28 (35.00)                             |

**Table 8.** Distribution of patients with hematoma according to combination antithrombotic therapy

| Antithrombotic therapy regimen               | No. of patients with hematoma (%) (n=80) |
|---------------------------------------------|----------------------------------------|
| Mono therapy                                | 30 (37.50)                             |
| Double therapy                              | 21 (26.25)                             |
| Triple therapy                              | 1 (1.25)                               |
| None                                        | 28 (35.00)                             |

**Table 9.** Distribution of patients with hematoma according to treatment method

| Treatment method                             | No. of patients with hematoma (%) (n=80) |
|---------------------------------------------|----------------------------------------|
| Aspiration only                             | 52 (65.00)                             |
| Aspiration + surgical procedure             | 6 (7.50)                               |
| Surgical procedure only (evacuation, implant removal, and other procedures) | 5 (6.25) |
| Conservative treatment (compression and observation) | 17 (21.25) |

**Table 10.** Results of aspiration in patients with hematoma

| Result                                     | No. of patients treated by aspiration (%) |
|---------------------------------------------|------------------------------------------|
| Clear                                       | 52 (89.65)                               |
| Complication                                | 6 (10.34)                                |
| Total                                       | 58 (100)                                 |

**Discussion**

The use of CIED has increased over the last decade due to diversifying indications and increasing life expectancy. One of the most common complications of the CIED procedure is the pocket hematoma, which can be small and may be managed conservatively [4,15]. In this study, we aimed to explore whether it would be possible to lower the risk of infection by aseptically removing the hematoma at an early stage through aspiration. We found that aseptic removal of hematoma by aspiration alone was effective in most patients. We noted a low complication rate, with complications that could not be attributed to the aspiration procedure. Only 10.34% of the patients...
had complications, i.e., cases where hematoma or pocket hematoma could not be treated with aspiration alone or cases where the condition exacerbated to infection, necessitating surgical intervention. Of the six patients who needed additional procedures to treat hematoma, one patient needed only incision, hematoma rolling, and primary closure. Three only required hematoma evacuation surgery because the hematoma size was not decreased by aspiration treatment alone. These patients did not present any symptoms of infection, and their hematoma was completely healed. Only two out of six patients in the complication group presented with severe infection symptoms, including uncontrolled pain with severe swelling, no reduction in bloody discharge through the incision site, rapid skin color change in the area where the device was inserted, and a continuous elevation of inflammatory markers such as erythrocyte sedimentation rate, C-reactive protein, and white blood cell counts soon after the CIED procedure. In these cases, infections were not caused by aspiration treatment. The two patients had hematoma evacuation surgery first because the condition of their wounds had worsened soon after the CIED procedure. Aspiration was only used in the postoperative period after evacuation surgery, suggesting that the infection was not caused by aspiration. Therefore, we can conclude that none of the 58 patients with hematoma treated using aspiration acquired the infection from the aspiration procedure.

Some studies have reported that pocket hematoma is more common among women than men and affects older adults more commonly [13,14,16]. Although our sample size was small, the hematoma was more common among men, contrary to previous reports. The results of the age-specific incidence rate, however, were in line with the findings of previous studies (i.e., higher incidence among older adults).

Patients receiving ICD or CRT implants were reportedly more likely to have pocket hematoma than those receiving permanent pacemakers [14]. Our results also aligned with these findings; in our study, the hematoma was more common among patients receiving ICD, with more patients having permanent pacemakers than CRT implants. It is known that device complexity and the number of leads were significantly associated with increased infection risk [17]. In one study, the infection risk was higher in implantable device replacement procedures than in first implants [18]. Also, patients with comorbidities such as congestive heart failure, renal failure, and thrombocytopenia have an increased risk of pocket hematoma formation [13,14].

Clinically significant pocket hematoma is associated with a higher risk of device infection, which is reportedly associated with a mortality rate of 0% to 18% [6-8,19,20]. There are several possible mechanisms of hematoma development that predispose patients to CIED infection. Some of these are: (1) postoperative contamination caused by tension from hematoma, which causes a breach in the wound, and (2) pressure from the hematoma may cause pressure-induced tissue necrosis and decrease the ability of local tissue to fight infection [21,22]. These conditions eventually create fertile ground for sustained microbial colonization.

Currently, there is no specific treatment for pocket hematomas in the immediate term, except for conservative treatment such as compression dressings [4,15]. Preventing pocket hematoma formation is challenging because patients who undergo CIED implantation or replacement are often on anticoagulant and antiplatelet therapy due to associated comorbidities [2]. As a result, current measures primarily focus on pre-operative strategies to reduce hematoma formation. For example, in terms of anticoagulant and antiplatelet therapy, withholding warfarin for 2–3 days before implantation in patients at low risk of thromboembolism can reduce the risk of pocket hematoma [23]. However, in patients with moderate-to-high risk of thromboembolism, oral anticoagulants should be continued to avoid a situation requiring bridging therapy during the CIEDs procedure [23]. In recent meta-analyses, the continuation of warfarin was reported as the best strategy for moderate-to-high-risk of thromboembolism in patients to reduce pocket hematoma formation [24]. Concomitant use of antiplatelet agents in patients undergoing device surgery doubles the risk of clinically significant hematoma. In our study, the patients’ intake of antiplatelet and anticoagulant medications was either interrupted or uninterrupted, depending on their condition. If a patient was at risk of pocket hematoma, the medication was discontinued before and after the CIED procedure. Consequently, even if a patient consumed the medication for the procedure before admission, interrupting the medication intake would decrease the final effect, thereby reducing the probability of hematoma formation among patients consuming anticoagulant and antiplatelet medications. This is evident from the higher-than-expected rate of pocket hematoma formation in the patients who did not receive any antiplatelet and anticoagulant therapy. Clinicians have also focused on optimizing the procedure itself to reduce the risk of hematoma formation. Such efforts include subcutaneous insertion of CIED (not in the subpectoral area) [5], irrigation of the pocket, meticulous
cauterization of all bleeding arteries, and use of absorbable hemostat (D-Stat Flowable Hemostat) [25].

Our study focused on exploring aspiration as the primary treatment method for pocket hematoma. This is contrary to the common understanding wherein aspiration is not recommended as a treatment for pocket hematoma due to the increased infection rate [6,9]. We found that aspiration was an effective method for hematoma treatment and caused no complications. Previous studies did not specify the specialty of the surgeon who performed aspiration as well as the procedure used for aspiration. In our study, the aspiration procedure was performed by plastic surgeons familiar with the procedure and surgery, and the patients were followed up by plastic surgeons who were trained as specialists in applying dressings. Furthermore, the procedure and post-dressing treatment after aspiration were not complex. Aspiration was not performed in an operating room; instead, it was performed aseptically in a private room for hospitalized patients and in our plastic surgery room for outpatients. Successful aspiration without any complications in this study further supports the feasibility of aspiration as an effective treatment for pocket hematoma. Our findings suggest that the procedure can be safely performed aseptically using alcohol and povidone preparation and aseptic gloves, taking care to avoid contact between the aspiration needle and the CIED implant. We also recommend using an ultrasound-guided aspiration for clinicians unfamiliar with the procedure.

One of the strengths of this study is that, since January 2011, the patients were followed up by both cardiologists and plastic surgeons in our hospital from the beginning of the CIED procedure to the resolution of pocket hematoma. This allowed us to capture high-quality data during the follow-up period. However, there were several limitations to our study. First, the patients were subject to anticoagulant and antiplatelet treatment, depending on each patient's condition, meaning that analysis of the actual effect of medication on pocket hematoma formation would have been impacted. Second, medical records and data were focused on patients with grade 2 or 3 pocket hematoma, for which aspiration therapy could be used. Consequently, a number of patients who received conservative treatment for grade 1 hematoma were missed, making the ratio of the conservative treatment patient group slightly lower than the actual figure.

In conclusion, clinicians must place much emphasis on reducing the risk of pocket hematoma formation, considering the high mortality rates and complications in the other studies mentioned above. Moreover, when planning a CIED procedure for patients with congestive heart failure, renal failure, and thrombocytopenia, which reportedly increase the risk of hematoma development, the CIED procedure must be carefully and meticulously planned, examining the risks and benefits.

While pocket hematoma formation could not be prevented despite knowledge of the risk factors from previous reports, we aimed to treat hematoma and to prevent it from aggravating to CIED infection. Our study confirmed that aspiration could be an effective treatment method for pocket hematoma.

Conflict of interest

This work was supported by Wonkwang University in 2021. Young Cheon Na is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

ORCID iDs

Hye Mi Lee https://orcid.org/0000-0003-3343-6137
Jin Woo Park https://orcid.org/0000-0003-4733-3227
Young Cheon Na https://orcid.org/0000-0003-3136-0351
Chi Sun Yoon https://orcid.org/0000-0002-9204-9121
Jong Hwan Kim https://orcid.org/0000-0003-4355-2692
Nam Ho Kim https://orcid.org/0000-0003-4559-5493

References

1. Kirkfeldt RE, Johansen JB, Nohr EA, et al. Complications after cardiac implantable electronic device implantations: an analysis of a complete, nationwide cohort in Denmark. Eur Heart J 2014;35:1186-94.
2. Stewart MH, Morin DP. Management of perioperative anticoagulation for device implantation. Card Electrophysiol Clin 2018;10:99-109.
3. Birnie DH, Healey JS, Wells GA, et al. Pacemaker or defibrillator surgery without interruption of anticoagulation. N Engl J Med 2013;368:2084-93.
4. Kutinsky IB, Jarandilla R, Jewett M, et al. Risk of hematoma complications after device implant in the clopidogrel era. Circ Arrhythm Electrophysiol 2010;3:312-8.
5. Wiegand UK, LeJeune D, Boguschewski F, et al. Pocket hematoma after pacemaker or implantable cardioverter defibrillator surgery: influence of patient morbidity, operation
strategy, and perioperative antiplatelet/anticoagulation therapy. Chest 2004;126:1177-86.
6. Essebag V, Verma A, Healey JS, et al. Clinically significant pocket hematoma increases long-term risk of device infection: BRUISE CONTROL INFECTION Study. J Am Coll Cardiol 2016;67:1300-8.
7. Sohail MR, Henrikson CA, Braid-Forbes MJ, et al. Mortality and cost associated with cardiovascular implantable electronic device infections. Arch Intern Med 2011;171:1821-8.
8. Tarakji KG, Chan Ej, Cantillon DJ, et al. Cardiac implantable electronic device infections: presentation, management, and patient outcomes. Heart Rhythm 2010;7:1043-7.
9. Klug D, Balde M, Pavin D, et al. Risk factors related to infections of implanted pacemakers and cardioverter-defibrillators: results of a large prospective study. Circulation 2007;116:1349-55.
10. Joy PS, Kumar G, Poole JE, et al. Cardiac implantable electronic device infections: who is at greatest risk? Heart Rhythm 2017;14:839-45.
11. Prutkin JM, Reynolds MR, Bao H, et al. Rates of and factors associated with infection in 200 909 Medicare implantable cardioverter-defibrillator implants: results from the National Cardiovascular Data Registry. Circulation 2014;130:1037-43.
12. DE Sensi F, Miracapillo G, Cresti A, et al. Pocket hematoma: a call for definition. Pacing Clin Electrophysiol 2015;38:909-13.
13. Sridhar AR, Yarlagadda V, Kanmantheerddy A, et al. Incidence, predictors and outcomes of hematoma after ICD implantation: an analysis of a nationwide database of 85,276 patients. Indian Pacing Electrophysiol J 2016;16:159-64.
14. Chen HC, Chen YL, Guo BF, et al. Thrombocytopenia, dual antiplatelet therapy, and heparin bridging strategy increase pocket hematoma complications in patients undergoing cardiac rhythm device implantation. Can J Cardiol 2013;29:1110-7.
15. Bernard ML, Shotwell M, Nietert PJ, et al. Meta-analysis of bleeding complications associated with cardiac rhythm device implantation. Circ Arrhythm Electrophysiol 2012;5:468-74.
16. Nowak B, Misselwitz B; Expert committee ‘Pacemaker’, Institute of Quality Assurance Hessen, et al. Do gender differences exist in pacemaker implantation? Results of an obligatory external quality control program. Europace 2010;12:210-5.
17. Olsen T, Jorgensen OD, Nielsen JC, et al. Incidence of device-related infection in 97 750 patients: clinical data from the complete Danish device-cohort (1982-2018). Eur Heart J 2019;40:1862-9.
18. Ferretto S, Mattesi G, Migliore F, et al. Clinical predictors of pocket hematoma after cardiac device implantation and replacement. J Cardiovasc Med (Hagerstown) 2020;21:123-7.
19. de Oliveira JC, Martinelli M, Nishioka SA, et al. Efficacy of antibiotic prophylaxis before the implantation of pacemakers and cardioverter-defibrillators: results of a large, prospective, randomized, double-blinded, placebo-controlled trial. Circ Arrhythm Electrophysiol 2009;2:29-34.
20. Baman TS, Gupta SK, Valle JA, et al. Risk factors for mortality in patients with cardiac device-related infection. Circ Arrhythm Electrophysiol 2009;2:129-34.
21. Turagam MK, Nagarajan DV, Bartus K, et al. Use of a pocket compression device for the prevention and treatment of pocket hematoma after pacemaker and defibrillator implantation (STOP-HEMATOMA-I). J Interv Card Electrophysiol 2017;49:197-204.
22. Da Costa A, Lelievre H, Kirkorian G, et al. Role of the preaxillary flora in pacemaker infections: a prospective study. Circulation 1998;97:1791-5.
23. Zhu DW, Ahmed I. Perioperative management of anticoagulation in patients on warfarin therapy undergoing surgery for cardiac implantable electronic devices. J Arrhythm 2013;29:162-7.
24. Du L, Zhang Y, Wang W, et al. Perioperative anticoagulation management in patients on chronic oral anticoagulant therapy undergoing cardiac devices implantation: a meta-analysis. Pacing Clin Electrophysiol 2014;37:1573-86.
25. Baddour LM, Epstein AE, Erickson CG, et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-77.